Anzeige
❌
Mehr »
Login
Samstag, 05.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Ist das der Durchbruch für den KI-Biotech-Geheimtipp?
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: A2QL00 | ISIN: US28617K1016 | Ticker-Symbol: 2TK
Stuttgart
04.04.25
21:57 Uhr
2,540 Euro
-0,280
-9,93 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ELEDON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ELEDON PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,5202,64004.04.
2,4802,68004.04.

Aktuelle News zur ELEDON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.03.Eledon Pharmaceuticals, Inc. - 10-K, Annual Report1SEC Filings
20.03.Eledon Pharmaceuticals GAAP EPS of -$0.75 misses by $0.041Seeking Alpha
20.03.Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results64GlobeNewswire (Europe)Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced...
► Artikel lesen
20.03.Eledon Pharmaceuticals, Inc. - 8-K, Current Report1SEC Filings
07.02.Eledon's tegoprubart used in second pig-to-human kidney transplant1Investing.com
07.02.Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human235GlobeNewswire (Europe)Patient treated in procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, was recently released from hospital Investigational therapy tegoprubart targets...
► Artikel lesen
13.01.Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook131GlobeNewswire (Europe)Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updated...
► Artikel lesen
20.12.24Eledon Pharmaceuticals, Inc. - 8-K, Current Report-SEC Filings
ELEDON PHARMACEUTICALS Aktie jetzt für 0€ handeln
13.11.24Eledon Pharmaceuticals GAAP EPS of -$0.32 misses by $0.022Seeking Alpha
12.11.24Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results379GlobeNewswire (Europe)Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive...
► Artikel lesen
12.11.24Eledon Pharmaceuticals, Inc. - 10-Q, Quarterly Report-SEC Filings
30.10.24Eledon drug helps transplants 'cure' type 1 diabetes-pharmaphorum
29.10.24Eledon Pharmaceuticals prices 18.36M shares at $3.65 in underwritten offering2Seeking Alpha
29.10.24Eledon Pharmaceuticals legt Bedingungen für Aktienemission über 85 Millionen US-Dollar fest1Investing.com Deutsch
29.10.24Eledon Pharmaceuticals sets terms for $85 million stock offering2Investing.com
29.10.24Eledon Pharmaceuticals, Inc. - 8-K, Current Report1SEC Filings
29.10.24Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet ...218GlobeNewswire (Europe)- First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose...
► Artikel lesen
04.09.24Eledon Pharmaceuticals, Inc.: Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients251GlobeNewswire (Europe)IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN) today announced that it has successfully completed enrollment for its Phase 2 BESTOW clinical...
► Artikel lesen
14.08.24Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results223GlobeNewswire (Europe)Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation 80 participants (two-thirds of projected recruitment)...
► Artikel lesen
29.07.24Eledon Pharmaceuticals, Inc.: Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection358GlobeNewswire (Europe)IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN) today announced that it has enrolled the 80th participant in its ongoing Phase 2 BESTOW trial...
► Artikel lesen
Seite:  1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1